Gary S. Hogge - 28 Dec 2021 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
SVP,Clinical & Medical Affairs
Signature
/s/ Grant Harbert, as Attorney-in Fact
Issuer symbol
LCTX
Transactions as of
28 Dec 2021
Net transactions value
-$596,225
Form type
4
Filing time
30 Dec 2021, 16:20:46 UTC
Next filing
15 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares, no par value Options Exercise $128,002 +185,000 +650% $0.6919 213,445 28 Dec 2021 Direct
transaction LCTX Common Shares, no par value Options Exercise $499,857 +236,899 +111% $2.11 450,344 28 Dec 2021 Direct
transaction LCTX Common Shares, no par value Options Exercise $90,845 +79,689 +18% $1.14 530,033 28 Dec 2021 Direct
transaction LCTX Common Shares, no par value Sale $1,228,891 -501,588 -95% $2.45 28,445 28 Dec 2021 Direct F1
transaction LCTX Common Shares, no par value Options Exercise $6,400 +9,250 +33% $0.6919 37,695 29 Dec 2021 Direct
transaction LCTX Common Shares, no par value Sale $23,032 -9,250 -25% $2.49 28,445 29 Dec 2021 Direct F2
transaction LCTX Common Shares, no par value Sale $69,406 -28,445 -100% $2.44 0 29 Dec 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (right to buy) Options Exercise $0 -185,000 -42% $0.000000 259,000 28 Dec 2021 Common Shares 185,000 $0.6919 Direct F4
transaction LCTX Employee Stock Option (right to buy) Options Exercise $0 -236,899 -96% $0.000000 10,301 28 Dec 2021 Common Shares 236,899 $2.11 Direct F5
transaction LCTX Employee Stock Option (right to buy) Options Exercise $0 -79,689 -71% $0.000000 32,811 28 Dec 2021 Common Shares 79,689 $1.14 Direct F6
transaction LCTX Employee Stock Option (right to buy) Options Exercise $0 -9,250 -3.6% $0.000000 249,750 29 Dec 2021 Common Shares 9,250 $0.6919 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.40 to not more than $2.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 The 9,250 shares sold on 12/29/21, were all sold at a transaction price of $2.49.
F3 The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.42 to not more than $2.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The reporting person was granted options on March 17, 2020, with an exercise price of $0.6919 per share to purchase up to 444,000 common shares of the issuer. One quarter of the options vested and became exercisable on March 17, 2021, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.
F5 The reporting person was granted options on February 11, 2018, with an exercise price of $2.11 per share to purchase up to 247,200 common shares of the issuer. One quarter of the options vested and became exercisable on February 11, 2019, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.
F6 The reporting person was granted options on February 12, 2019, with an exercise price of $1.14 per share to purchase up to 112,500 common shares of the issuer. One quarter of the options vested and became exercisable on February 12, 2020, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.

Remarks:

Exhibit 24 - Power of Attorney